Effect of rosa canina on non alcoholic fatty liver disaese

The effect of rosa canina supplement on liver enzymes, lipid profile, fasting blood glucose and anthropometric indices in patients with non-alcoholic fatty liver disease under weight loss diet

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230903059334N1

Enrollment

116

Registered

2023-10-16

Start date

2023-10-23

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alchoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: The intervention group will be given a weight loss diet and 1 gram of rosa canina 2 times a day in the form of 500 mg capsules with a glass of water in the morning

It should be noted that this placebo will look exactly the same as the rosa canina capsule. Starch powder will be used for placebo capsules. Placebo capsules will be prepared by the Faculty of Pharmac

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: All people with non-alcoholic fatty liver disease referring to Internist

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Liver enzymes. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Pars azmoon liver enzymes kit.;Lipid profile. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Pars Azmoun Cholesterol Quantification Kit.;Fasting blood sugar. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Glucose Quantification Kit Pars Azman.;Body weight. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Seca scale.	—

Measure

Time frame

Liver enzymes. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Pars azmoon liver enzymes kit.;Lipid profile. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Pars Azmoun Cholesterol Quantification Kit.;Fasting blood sugar. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Glucose Quantification Kit Pars Azman.;Body weight. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Seca scale.

—

Secondary

Measure	Time frame
Blood pressure. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Barometer.;Waist circulate. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Measuring tape.;Body fat mass. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Inbody body analyzer.;Body muscle mass. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Inbody body analyzer.	—

Measure

Time frame

Blood pressure. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Barometer.;Waist circulate. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Measuring tape.;Body fat mass. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Inbody body analyzer.;Body muscle mass. Timepoint: At the beginning of the study and 8 weeks after the start of taking rosa canina supplement. Method of measurement: Inbody body analyzer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahideh Aghamohammadi khiavi

Khalkhal university of medical science

v_agamohammadi@yahoo.com32426801

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026